Abstract
NKG2D is an activating immune receptor expressed by NK and effector T cells. Induced expression of NKG2D ligand on tumor cell surface during oncogenic insults renders cancer cells susceptible to immune destruction. In advanced human cancers, tumor cells shed NKG2D ligand to produce an immune soluble form as a means of immune evasion. Soluble NKG2D ligands have been associated with poor clinical prognosis in cancer patients. Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years. In this review, we will discuss the progress and perspectives.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 55-61 |
| Number of pages | 7 |
| Journal | Current Opinion in Immunology |
| Volume | 51 |
| DOIs | |
| State | Published - Apr 2018 |
Funding
Supported by National Institute of Health (grant number R01CA 208246 and R01CA204021 ) and DOD USARMC (Award W81XWH150406) to JDW.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
